Levi & Korsinsky Alerts Regeneron Investors of Pending Class Action Lawsuit with Key Deadline Approaching

Overview of the Class Action Lawsuit

Levi & Korsinsky, LLP has recently issued a notice to investors of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit that addresses securities fraud allegations. This legal action involves claims that certain misleading statements impacted investors’ financial standing between November 2, 2023, and October 30, 2024. The firm is encouraging affected Regeneron investors to take action before the lead plaintiff deadline of March 10, 2025.

Key Details of the Allegations

The allegations against Regeneron suggest that the company engaged in deceptive practices regarding its primary product, Eylea. Specifically, the complaint contends that Regeneron made false claims regarding payments related to credit card usage. It is alleged that the company paid distributors to ensure they wouldn’t charge customers more for using credit cards to purchase Eylea. In turn, these payments are claimed to have effectively subsidized customer prices when paying via credit cards.

Such financial maneuvers allegedly allowed Regeneron to misrepresent its sales figures for Eylea, suggesting a healthier demand than what genuinely was the case. Moreover, by failing to categorize these credit card fees as price concessions, the company purportedly inflated the Average Selling Price (ASP) reported to federal agencies, leading to violations of the False Claims Act.

Implications for Investors

Investors in Regeneron who have suffered losses during the designated time frame may have grounds to join this class action lawsuit. The firm emphasizes that potential plaintiffs are not required to take on the responsibility of being lead plaintiff to share in any potential compensation. Essentially, regaining lost investments may be possible at no cost — affected shareholders can participate without initial fees or obligations.

Why Choose Levi & Korsinsky?

Experience matters in complex legal matters, and Levi & Korsinsky brings two decades of expertise in securities litigation, having secured substantial settlements for investors. The firm has a robust track record highlighted by a dedicated team of over 70 professionals, reaffirming its commitment to representing investor interests diligently. As recognized by ISS Securities Class Action Services, the firm consistently ranks among the top securities litigation firms in the United States, assuring clients of their credibility and focus.

Next Steps for Interested Investors

For Regeneron investors wishing to join the lawsuit, it is crucial to act promptly, as the opportunity to become a lead plaintiff will expire on March 10, 2025. Interested parties can reach out to Levi & Korsinsky for further details and assistance in securing their legal rights. Contact information includes email options for inquiries as well as a direct line to the firm’s office in New York City.

In conclusion, this evolving case against Regeneron Pharmaceuticals may offer a chance for impacted shareholders to seek restitution. With the deadline fast approaching, those affected are encouraged to explore their options for legal recourse and consider contributing to the class action's advancement toward justice and accountability.